Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.

Berdeja JG, Heinrich MC, Dakhil SR, Goldberg SL, Wadleigh M, Kuriakose P, Cortes J, Radich J, Helton B, Rizzieri D, Paley C, Dautaj I, Mauro MJ.

Leuk Lymphoma. 2019 Mar 26:1-10. doi: 10.1080/10428194.2019.1590569. [Epub ahead of print]

PMID:
30912699
2.

Reflections on percutaneous therapies for secondary mitral regurgitation.

Goldberg SL.

Cardiovasc Revasc Med. 2019 Jun;20(6):528-529. doi: 10.1016/j.carrev.2019.02.027. Epub 2019 Mar 15. No abstract available.

PMID:
30905660
3.

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.

Garcia-Manero G, Almeida A, Fenaux P, Gattermann N, Giagounidis A, Goldberg SL, Ozawa K, Weaver J, Santini V.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):213-219.e4. doi: 10.1016/j.clml.2018.12.012. Epub 2018 Dec 21.

PMID:
30770308
4.

Development of a Precise, Clinically Relevant, Digital Classification Schema for Cancer.

Pecora AL, Norden AD, Hervey J, Schultz EV, Gallucci TL, Rushforth E, Goldberg SL.

JCO Clin Cancer Inform. 2018 Dec;2:1-10. doi: 10.1200/CCI.18.00006.

5.

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, Michallet M, Simonsson B, Williams LA, Gajavelli S, DeGutis I, Sen GP, Paquette RL.

Am J Hematol. 2019 Jan;94(1):46-54. doi: 10.1002/ajh.25306. Epub 2018 Oct 31.

6.

A Patient-Reported Outcome Instrument to Assess Symptom Burden and Predict Survival in Patients with Advanced Cancer: Flipping the Paradigm to Improve Timing of Palliative and End-of-Life Discussions and Reduce Unwanted Health Care Costs.

Goldberg SL, Paramanathan D, Khoury R, Patel S, Jagun D, Arunajadai S, DeVincenzo V, Benito RP, Gruman B, Kaur S, Paddock S, Norden AD, Schultz EV, Hervey J, Jordan T, Goy A, Pecora AL.

Oncologist. 2019 Jan;24(1):76-85. doi: 10.1634/theoncologist.2018-0238. Epub 2018 Sep 28.

PMID:
30266893
7.

Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives.

O'Neill SC, Taylor KL, Clapp J, Jayasekera J, Isaacs C, Mary Atieh Graham D, Goldberg SL, Mandelblatt J.

J Health Commun. 2018;23(7):679-686. doi: 10.1080/10810730.2018.1506836. Epub 2018 Aug 21.

PMID:
30130477
8.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

9.

Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.

Almeida A, Fenaux P, Garcia-Manero G, Goldberg SL, Gröpper S, Jonasova A, Vey N, Castaneda C, Zhong J, Beach CL, Santini V.

Leuk Lymphoma. 2018 Sep;59(9):2135-2143. doi: 10.1080/10428194.2017.1421758. Epub 2018 Jan 11.

PMID:
29322849
10.

Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia.

Goldberg SL, Savona M, Mauro MJ.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):98-105. doi: 10.1016/j.clml.2017.11.006. Epub 2017 Nov 29. Review.

11.

Real-world economic value of a 21-gene assay in early-stage breast cancer.

Waintraub SE, McNamara D, Graham DMA, Pecora AL, Min J, Wu T, Noh HG, Connors J, Pe Benito R, Choi K, Schultz E, Goldberg SL.

Am J Manag Care. 2017 Dec 1;23(12):e416-e420.

12.

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ.

Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. Epub 2017 Sep 25.

13.

Treatment of Peripheral T-Cell Lymphoma in Community Settings.

Feldman T, Farber CM, Choi K, Faria C, Goy A, Connors J, Paramanathan D, Kaur S, Schultz E, McGuire M, Goldberg SL.

Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):354-361. doi: 10.1016/j.clml.2017.05.001. Epub 2017 May 10.

PMID:
28622960
14.

A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure-Trial design of the REDUCE FMR study.

Goldberg SL, Meredith I, Marwick T, Haluska BA, Lipiecki J, Siminiak T, Mehta N, Kaye DM, Sievert H; REDUCE FMR Investigators.

Am Heart J. 2017 Jun;188:167-174. doi: 10.1016/j.ahj.2017.02.032. Epub 2017 Mar 6.

15.

Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.

Gutierrez ME, Choi K, Lanman RB, Licitra EJ, Skrzypczak SM, Pe Benito R, Wu T, Arunajadai S, Kaur S, Harper H, Pecora AL, Schultz EV, Goldberg SL.

Clin Lung Cancer. 2017 Nov;18(6):651-659. doi: 10.1016/j.cllc.2017.04.004. Epub 2017 Apr 13.

16.

Coronary Sinus-Based Approach to Mitral Regurgitation.

Goldberg SL, Hammerstingl C.

Interv Cardiol Clin. 2016 Jan;5(1):93-100. doi: 10.1016/j.iccl.2015.08.008. Epub 2015 Oct 6. Review.

PMID:
27852485
17.

Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial.

Lipiecki J, Siminiak T, Sievert H, Müller-Ehmsen J, Degen H, Wu JC, Schandrin C, Kalmucki P, Hofmann I, Reuter D, Goldberg SL, Haude M.

Open Heart. 2016 Jul 8;3(2):e000411. doi: 10.1136/openhrt-2016-000411. eCollection 2016.

18.

A Patient-Reported Outcome Instrument to Facilitate Timing of End-of-Life Discussions among Patients with Advanced Cancers.

Goldberg SL, Pecora AL, Contreras J, DeMarco KE, Paramanathan D, DeVincenzo V, Schultz E, Choi K.

J Palliat Med. 2016 Oct;19(10):1092-1097. Epub 2016 Jun 27.

PMID:
27348597
19.

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot F.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):341-349.e1. doi: 10.1016/j.clml.2016.03.004. Epub 2016 Mar 29.

PMID:
27133948
20.

Biotechnology Based Process for Production of a Disulfide-Bridged Peptide.

Goswami A, Goldberg SL, Hanson RL, Johnston RM, Lyngberg OK, Chan Y, Lo E, Chan SH, de Mas N, Ramirez A, Doyle R, Ding W, Gao M, Krystek SR Jr, Wan C, Kim YJ, Calambur D, Witmer M, Bryson JW.

Bioconjug Chem. 2016 May 18;27(5):1276-84. doi: 10.1021/acs.bioconjchem.6b00101. Epub 2016 May 2.

PMID:
27098672
21.

Percutaneous Repair of Aortic Pseudoaneurysms: A Case Series.

Steinberg ZL, Don CW, Sun JC, Gill EA Jr, Goldberg SL.

J Invasive Cardiol. 2016 Jan;28(1):E6-E10.

22.

Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities.

Goldberg SL.

Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):711-4. doi: 10.1016/j.clml.2015.08.088. Epub 2015 Sep 2.

PMID:
26433907
23.

The CARILLON Mitral Contour transcatheter indirect mitral valve annuloplasty system.

Goldberg SL, Lipiecki J, Sievert H.

EuroIntervention. 2015 Sep;11 Suppl W:W64-6. doi: 10.4244/EIJV11SWA18. No abstract available.

24.

Granulomatosis With Polyangiitis Presenting With an Intracardiac Mass and Complete Heart Block: Enhanced Images by 3-Dimensional Echocardiography.

Taskesen T, Goldberg SL, Mannelli L, Rabkin D, Hawn TR, Fligner CL, Cormack F, Gill EA.

Circulation. 2015 Sep 8;132(10):961-4. doi: 10.1161/CIRCULATIONAHA.115.016851. No abstract available.

25.

Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings.

Borisenko O, Haude M, Hoppe UC, Siminiak T, Lipiecki J, Goldberg SL, Mehta N, Bouknight OV, Bjessmo S, Reuter DG.

BMC Cardiovasc Disord. 2015 May 14;15:43. doi: 10.1186/s12872-015-0039-8.

26.

Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.

Goldberg SL, Akard LP, Dugan MJ, Faderl S, Pecora AL.

J Oncol Pract. 2015 May;11(3):e398-404. doi: 10.1200/JOP.2014.001099. Epub 2015 Mar 10.

PMID:
25758446
27.

Gerbode defect: Another nail for the 3D transesophagel echo hammer?

Taskesen T, Prouse AF, Goldberg SL, Gill EA.

Int J Cardiovasc Imaging. 2015 Apr;31(4):753-64. doi: 10.1007/s10554-015-0620-3. Epub 2015 Feb 14. Review.

PMID:
25680357
28.

Predictors of Food Insecurity among Older Adults in the United States.

Goldberg SL, Mawn BE.

Public Health Nurs. 2015 Sep-Oct;32(5):397-407. doi: 10.1111/phn.12173. Epub 2014 Dec 23.

PMID:
25534664
29.

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE.

Cancer. 2015 Jan 15;121(2):234-42. doi: 10.1002/cncr.28974. Epub 2014 Sep 15.

30.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

31.

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.

Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P.

Leuk Res Rep. 2014 Jul 5;3(2):58-61. doi: 10.1016/j.lrr.2014.06.003. eCollection 2014.

32.

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.

Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP.

Br J Haematol. 2014 Oct;167(2):185-93. doi: 10.1111/bjh.13016. Epub 2014 Jul 8.

33.

Role of three-dimensional echocardiography in management of acquired intracardiac shunts.

Taskesen T, Goldberg SL, Gill EA.

Echocardiography. 2014 Sep;31(8):E250-3. doi: 10.1111/echo.12682. Epub 2014 Jul 5.

PMID:
25039665
34.

The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.

Donato ML, Siegel DS, Vesole DH, McKiernan P, Nyirenda T, Pecora AL, Baker M, Goldberg SL, Mato A, Goy A, Rowley SD.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1211-6. doi: 10.1016/j.bbmt.2014.04.027. Epub 2014 May 2.

35.

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL.

Curr Med Res Opin. 2014 Jul;30(7):1345-52. doi: 10.1185/03007995.2014.904281. Epub 2014 Mar 21.

PMID:
24640967
36.

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.

Akard LP, Cortes JE, Albitar M, Goldberg SL, Warsi G, Wetzler M, Ericson SG, Radich JP.

Arch Pathol Lab Med. 2014 Sep;138(9):1186-92. doi: 10.5858/arpa.2013-0584-OA. Epub 2013 Dec 5.

PMID:
24308645
37.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL.

J Med Econ. 2014 Feb;17(2):89-98. doi: 10.3111/13696998.2013.862251. Epub 2013 Nov 26.

PMID:
24188054
38.

The future of innovation in interventional cardiology--have we left the golden era?

Goldberg SL.

J Invasive Cardiol. 2013 Nov;25(11):566. No abstract available.

39.

Response to comment on "The placental mammal ancestor and the post-K-Pg radiation of placentals".

O'Leary MA, Bloch JI, Flynn JJ, Gaudin TJ, Giallombardo A, Giannini NP, Goldberg SL, Kraatz BP, Luo ZX, Meng J, Ni X, Novacek MJ, Perini FA, Randall Z, Rougier GW, Sargis EJ, Silcox MT, Simmons NB, Spaulding M, Velazco PM, Weksler M, Wible JR, Cirranello AL.

Science. 2013 Aug 9;341(6146):613. doi: 10.1126/science.1238162.

40.

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.

Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ.

Curr Med Res Opin. 2013 Sep;29(9):1075-82. doi: 10.1185/03007995.2013.812034. Epub 2013 Jun 21.

PMID:
23738923
41.

Invasive thoughts: Should we abandon femoral access for STEMIs?

Goldberg SL.

J Invasive Cardiol. 2013 May;25(5):210. No abstract available.

42.

The palatability and tolerability of deferasirox taken with different beverages or foods.

Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E.

Pediatr Blood Cancer. 2013 Sep;60(9):1507-12. doi: 10.1002/pbc.24561. Epub 2013 Apr 23.

PMID:
23637051
43.

The placental mammal ancestor and the post-K-Pg radiation of placentals.

O'Leary MA, Bloch JI, Flynn JJ, Gaudin TJ, Giallombardo A, Giannini NP, Goldberg SL, Kraatz BP, Luo ZX, Meng J, Ni X, Novacek MJ, Perini FA, Randall ZS, Rougier GW, Sargis EJ, Silcox MT, Simmons NB, Spaulding M, Velazco PM, Weksler M, Wible JR, Cirranello AL.

Science. 2013 Feb 8;339(6120):662-7. doi: 10.1126/science.1229237.

44.

A respectable result? Or do we need more closure?

Goldberg SL.

J Invasive Cardiol. 2012 Dec;24(12):623. No abstract available.

45.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W.

Lancet Oncol. 2012 Nov;13(11):1096-104. doi: 10.1016/S1470-2045(12)70436-9. Epub 2012 Oct 15.

46.

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.

Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF.

Leukemia. 2013 Apr;27(4):977-80. doi: 10.1038/leu.2012.264. Epub 2012 Sep 11. No abstract available.

PMID:
23032694
47.

Moving to (more) universal health care.

Goldberg SL.

J Invasive Cardiol. 2012 Aug;24(8):373. No abstract available.

48.

The Society for Cardiovascular Angiography and Interventions Structural Heart Disease Early Career Task Force survey results: endorsed by the Society for Cardiovascular Angiography and Interventions.

Marmagkiolis K, Hakeem A, Cilingiroglu M, Bailey SR, Ruiz C, Hijazi ZM, Herrmann HC, Zajarias A, Goldberg SL, Feldman T.

Catheter Cardiovasc Interv. 2012 Oct 1;80(4):706-11. doi: 10.1002/ccd.24535. Epub 2012 Jul 30.

PMID:
22745016
49.

Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial.

Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG.

Eur J Heart Fail. 2012 Aug;14(8):931-8. doi: 10.1093/eurjhf/hfs076. Epub 2012 May 21.

50.

Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.

Goldberg SL, Chen E, Sasane M, Paley C, Guo A, Laouri M.

Transfusion. 2012 Oct;52(10):2131-8. doi: 10.1111/j.1537-2995.2012.03626.x. Epub 2012 Apr 9.

PMID:
22486790

Supplemental Content

Loading ...
Support Center